Blood
Articles in this Issue
Khsrp depletion selectively eliminates AML cells that persist after venetoclax/azacitidine therapy via modulating SLC23A1-transported TET enzyme cofactors
Abstract Despite improved targeted therapies and chemotherapy regimens for acute myeloid leukemia (AML), durable remissions remain elusive f...
Inhibition of lysine acetyltransferases p300/CBP overcomes BTK inhibitor resistance in a xenograft model of Mantle Cell Lymphoma by suppressing MYC signaling
Abstract Background Bruton's tyrosine kinase inhibitors (BTKis) have improved outcomes for patients with relapsed/refractory mantle cell lym...
ONC001: A first-in-class ADC targeting CD64 for the treatment of monocytic leukemia developed through patient-guided target and payload selection
Abstract Background: Chronic myelomonocytic and acute monocytic leukemias (CMML and M4/M5 AML) display poor response to SoC therapies and lo...
T-cell engager activity of etentamig (BCMA x CD3) is potentiated by daratumumab in preclinical models of multiple myeloma
Abstract Introduction: Etentamig is a differentiated, 2nd generation, BCMA x CD3 bispecific T-cell engager composed of a high avidity bivale...
High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time: Results from the ATALANTA-1 MCL cohort
Abstract Introduction:MCL remains incurable, and patients (pts) with relapsed/refractory (R/R) disease following Bruton tyrosine kinase inhi...
Infections in patients with aggressive B-cell lymphomas treated with CD3xCD20 bispecific antibodies
Abstract Introduction CD3xCD20 bispecific antibodies (BsAbs) can provide durable responses for patients with aggressive...
Analysis of the cost-effectiveness without compromising clinical outcomes in outpatient CD19-directed CAR-T therapy in non-Hodgkin lymphoma patients at a community-based medical center
Abstract Context: Since FDA approval in 2017, CAR-T therapies have transformed treatment for hematologic malignancies; however, most CAR-T i...
Tissue specific requirement for the inv(16) oncogene CBFB::MYH11 implies unique leukemia survival mechanisms in the bone marrow microenvironment
Abstract Inversion of chromosome 16 [inv(16)] generates the oncogenic fusion gene Cbfb::MYH11 (CM) which isknown to initiate leukemogenesis...
Cytogenetics-based clinical trajectories of patients with MRD negativity post autologous stem cell transplant for multiple myeloma
Abstract Background Measurable residual disease (MRD) negativity post- autologous stem cell transplantation (ASCT) in newly diagnosed multip...
Glofitamab use may significantly reduce the efficacy of CAR-T therapy in R/R DLBCL patients
Abstract Background Glofitamab (a CD20×CD3 bispecific antibody) has been approved for the treatment of relapsed/refractory diffuse large B-c...
IHP-102 reduces pain and modulates complement activation in a sickle cell mouse model
Abstract Background: Sickle cell disease (SCD) is characterized by painful vaso-occlusive events (VOEs) initiated by white blood cell (WBC)...
The long non-coding RNA WT1-AS controls differentiation programs and leukemic cell fate in AML
Abstract Therapy of AML patients remains challenging due to high rates of relapses even after intensive treatment. Relapses are mostly cause...
Novel mechanisms of cell-based blood coagulation: Roles of integrin β3 psi domain and its L33P polymorphism
Abstract Integrin αIIbβ3 is the essential platelet receptor for hemostasis and thrombosis. The plexin-semaphorin-integrin (PSI) domain is an...
A simple scoring system for response and toxicity following lymphoma CAR-T: Results from the Australian CAR-T real-world consortium
Abstract Aim: Autologous anti-CD19 chimeric antigen receptor T-cell therapy (CAR-T) is now a standard-of-care for relapsed and/or refractory...
A Phase II study of azacitidine, venetoclax, and gilteritinib for newly diagnosed adverse risk FLT3-wild type acute myeloid leukemia
Abstract Introduction: Outcomes of patients (pts) with newly diagnosed (ND) acute myeloid leukemia (AML) and adverse-risk cytomolecular feat...
Prognostic significance of PNH clones in aplastic anemia treated with immunosuppression or allogeneic HSCT
Abstract Background: Aplastic anemia (AA) is a type of bone marrow failure caused by immune-mediated destruction of hematopoietic stem cells...
Inflammatory transcriptome dominates Indian AML: High iscore predicts poor outcomes even in genomically favorable subtypes and reveals regional immune-molecular divergence
Abstract Inflammation is increasingly recognized as a key modifier of AML outcomes, independent of genomic risk. A validated inflammation ge...
Impact of autoimmune disease on clinical outcomes in patients undergoing CAR T-cell therapy: A real-world analysis
Abstract Background: Chimeric antigen receptor T-cell (CAR-T) therapy is an established management of relapsed and refra...
Matched sibling donors still provide superior survival outcomes in older patients with AML in second complete remission. a study from the global committee and the acute leukemia working party of the european society for blood and marrow transplantation
Abstract Introduction Acute myeloid leukemia (AML) is a disease of older patients, with a median age at diagnosis of 68 years. Accumulating...
Development of an online bone marrow transplant (BMT) service medical education platform for internal medicine (IM) residents: A pilot study
Abstract Introduction: Studies demonstrate that less than 50% of Internal Medicine (IM) resident physicians feel comfortable caring for canc...
SMARCD1 subunit of SWI/SNF chromatin remodeling complexes collaborates with p53 to exert an oncogenic role in B-ALL by maintaining high metabolic activity
Abstract B-cell acute lymphoblastic leukemia (B-ALL) is the most common pediatric hematological malignancy. While advances in modern medicin...
Phase 3 Study of ivosidenib (IVO) and azacitidine (AZA) with or without venetoclax in adult patients with newly diagnosed IDH1-mutated AML or MDS/AML ineligible for intensive chemotherapy (EVOLVE-1)
Abstract Background: Acute myeloid leukemia (AML) is a clonal hematopoietic stem cell disorder characterized by the infiltration of the bone...
Successful bone marrow transplantation in 20 patients with severe congenital neutropenia using an immunosuppressive conditioning regimen: Results of a single institute
Abstract Severe congenital neutropenia (SCN) is a rare heterogeneous genetic disorder characterized by recurrent bacterial infections from e...
A chemo-free tumor microenvironment (TME) reshaping regimen combining glofitamab induces a high CR rate in relapsed/refractory diffuse large B cell lymphoma (DLBCL)
Abstract Background Outcomes of relapsed/refractory (R/R) diffuse large B cell lymphoma（DLBCL）are poor. Drug resistance and patient unfitne...
New fitusiran 10 mg dose increases proportion of people with hemophilia within target antithrombin range of 15–35%
Abstract Introduction Fitusiran is an antithrombin (AT)-lowering therapeutic that increases thrombin generation to restore hemostasis in peo...